<code id='E4970D25F7'></code><style id='E4970D25F7'></style>
    • <acronym id='E4970D25F7'></acronym>
      <center id='E4970D25F7'><center id='E4970D25F7'><tfoot id='E4970D25F7'></tfoot></center><abbr id='E4970D25F7'><dir id='E4970D25F7'><tfoot id='E4970D25F7'></tfoot><noframes id='E4970D25F7'>

    • <optgroup id='E4970D25F7'><strike id='E4970D25F7'><sup id='E4970D25F7'></sup></strike><code id='E4970D25F7'></code></optgroup>
        1. <b id='E4970D25F7'><label id='E4970D25F7'><select id='E4970D25F7'><dt id='E4970D25F7'><span id='E4970D25F7'></span></dt></select></label></b><u id='E4970D25F7'></u>
          <i id='E4970D25F7'><strike id='E4970D25F7'><tt id='E4970D25F7'><pre id='E4970D25F7'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:77658
          Exterior photo of UnitedHealth Group building
          UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

          There’s now a two-party showdown for one of the largest home health companies in the country.

          UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

          advertisement

          The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          Lawsuit highlights wrinkle for disputes over surprise medical bills
          Lawsuit highlights wrinkle for disputes over surprise medical bills

          EdUthmanAfterCongressofficiallyoutlawedsurprisemedicalbillslastyear,there’sbeenendless,litigiousdeba

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Wegovy, Zepbound and weight loss drugs that preserve muscle

          AdobeHaveyoueverseenamousewithasetofmusclesmoreappropriateforabodybuilderorcomicbooksuperhero?Well,2